Jasper Therapeutics Company Insiders
| JSPRW Stock | USD 0.20 0.02 9.09% |
Jasper Therapeutics employs about 45 people. The company is managed by 16 executives with a total tenure of roughly 105 years, averaging almost 6.0 years of service per executive, having 2.81 employees per reported executive. Recap of Jasper Therapeutics' management performance can provide insight into the venture performance.
Jasper |
Jasper Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4092) % which means that it has lost $0.4092 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7146) %, meaning that it generated substantial loss on money invested by shareholders. Jasper Therapeutics' management efficiency ratios could be used to measure how well Jasper Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.71 in 2024. Return On Capital Employed is likely to drop to -0.88 in 2024. Other Current Assets is likely to climb to about 1.9 M in 2024, whereas Total Assets are likely to drop slightly above 63.2 M in 2024.Common Stock Shares Outstanding is likely to climb to about 11 M in 2024, whereas Net Loss is likely to drop (6.1 M) in 2024.
Jasper Therapeutics Workforce Comparison
Jasper Therapeutics is rated second overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 173. Jasper Therapeutics totals roughly 45.0 in number of employees claiming about 26% of equities under Health Care industry.
Jasper Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Jasper Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Jasper Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Jasper Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kapoor Vishal over two months ago Insider Trading | ||
Mahal Jeetinder Singh over two months ago Disposition of tradable shares by Mahal Jeetinder Singh of Jasper Therapeutics subject to Rule 16b-3 | ||
Carlyle Group Inc. over three months ago Acquisition by Carlyle Group Inc. of 3133333 shares of Jasper Therapeutics at 1.5 subject to Rule 16b-3 | ||
Hoffen Howard I over six months ago Acquisition by Hoffen Howard I of 2300000 shares of Jasper Therapeutics subject to Rule 16b-3 | ||
Emster Kurt Von over six months ago Acquisition by Emster Kurt Von of 47000 shares of Jasper Therapeutics at 1.6 subject to Rule 16b-3 | ||
Hoffen Howard I over six months ago Acquisition by Hoffen Howard I of 200000 shares of Jasper Therapeutics subject to Rule 16b-3 |
Jasper Therapeutics Notable Stakeholders
A Jasper Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Jasper Therapeutics often face trade-offs trying to please all of them. Jasper Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Jasper Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ronald Martell | CEO President | Profile | |
| Herbert Cross | CFO Secretary | Profile | |
| Herbert CPA | CFO Secretary | Profile | |
| Judith MD | CoFounder Director | Profile | |
| William Lis | Ex CEO | Profile | |
| Luca Noto | Senior Operations | Profile | |
| Carol Zoltowski | VP Quality | Profile | |
| Jeetinder MBA | Chief Officer | Profile | |
| Wendy MD | Senior Medicine | Profile | |
| Jeet MBA | Chief Officer | Profile | |
| Patricia Carlos | Senior Quality | Profile | |
| Matthew Ford | Vice Resources | Profile | |
| Edwin MD | Chief Officer | Profile | |
| Susan Prohaska | VP CoFounder | Profile | |
| Kevin MD | Ex RD | Profile | |
| David MD | Portfolio Development | Profile |
About Jasper Therapeutics Management Performance
The success or failure of an entity such as Jasper Therapeutics often depends on how effective the management is. Jasper Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Jasper management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Jasper management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.68) | (0.71) | |
| Return On Capital Employed | (0.83) | (0.88) | |
| Return On Assets | (0.68) | (0.71) | |
| Return On Equity | (0.82) | (0.78) |
Please note, the imprecision that can be found in Jasper Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Jasper Therapeutics. Check Jasper Therapeutics' Beneish M Score to see the likelihood of Jasper Therapeutics' management manipulating its earnings.
Jasper Therapeutics Workforce Analysis
Traditionally, organizations such as Jasper Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Jasper Therapeutics within its industry.Jasper Therapeutics Manpower Efficiency
Return on Jasper Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.4M | |
| Net Loss Per Executive | 4M | |
| Working Capital Per Employee | 1.7M | |
| Working Capital Per Executive | 4.8M |
Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.